In re Application of: Twardzik et al.

Application No.: 10/039,119

Filed: January 4, 2002

Page 5



**PATENT** Attorney Docket No.: STEM1110-4

RECEIVED

APR 0 8 2002

## REGARDING THE AMENDMENTS TECH CENTER 1600 2900

The amendments to the written description are fully supported by the application, as filed. Specifically, support for the amendments adding Asp as one of the possibilities for  $X_3$  may be found in the Sequence Listings filed in the applications to which the present application claims priority. These applications are Application Serial Nos. 09/641,587, 09/492,935 and 09/378,567, all pending, and all incorporated by reference into the present invention. In the Sequence Listings filed in 09/492,935 and 09/378,567, SEQ ID NO.: 1 is the native sequence of human TGF $\alpha$ . It can be seen from the SEQ ID NO.: 1 that the amino acid in position #7 is Asp. Therefore, inclusion of Asp as an option for  $X_3$  is supported. Support for the amendment to the specification in formula IV, amending Gln to Asn is also supported by SEQ ID NO.: 1. In SEQ ID NO.: 1, it can be seen that the amino acid in position #6 is Asn. Therefore this amendment has been made to the specification. Similarly, the specification has been amended where it is stated, "wherein T is the native sequence of human TGFα (SEQ ID NO.:1) from amino acid #8 (Cys) to amino acid #44 (Cys)..." However, as can be seen in SEQ ID NO.: 1, in the native sequence of human TGFα amino acid #44 is not Cys, but Glu. The Cys that was referred to is in position #43. Therefore amendment of the position number has been made to the specification to correctly identify the Cys residue. Any other amendments to the written description have been made for clarification. These amendments are the addition of the word "or" between the values of -NH<sub>2</sub> and R<sub>3</sub> - X<sub>3</sub> for R<sub>1</sub>, the clarification of X<sub>1</sub> as  $X_{1a}$ ,  $X_{1b}$  or  $X_{1c}$ , the addition of sequence identification numbers and the correction of typographical errors. None of the amendments to the written description add any new matter.

## **CONCLUSION**

This Preliminary Amendment is submitted in order to clarify the invention. No new matter has been added. The new claims are supported by the specification and claims, as originally filed, as set forth above.

In re Application of: Twardzik et al.

Application No.: 10/039,119

Filed: January 4, 2002

Page 6

PATENT Attorney Docket No.: STEM1110-4

In view of the foregoing, Applicants respectfully submit that the claims are in condition

for allowance. No fee is deemed necessary in connection with the filing of this response.

However, if any fee is deemed necessary, the Commissioner is authorized to charge (or apply

any credits to) Deposit Account No.: 50-1355. The Examiner is invited to contact Applicant's

undersigned representative if there are any questions related to this matter.

Respectfully submitted,

Dated: March 25, 2002

Lisa A. Haile, J.D., Ph.D.

Registration No. 38,347 Telephone: 858-677-1456 Facsimile: 858-677-1465

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1100 San Diego, CA 92121-2133

**USPTO Customer Number 28213**